Opko Health (NASDAQ: OPK) and Astrazeneca PLC (NYSE:AZN) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, analyst recommendations and risk.
This is a summary of recent ratings and recommmendations for Opko Health and Astrazeneca PLC, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Opko Health presently has a consensus target price of $15.25, indicating a potential upside of 155.44%. Astrazeneca PLC has a consensus target price of $35.87, indicating a potential upside of 10.28%. Given Opko Health’s stronger consensus rating and higher possible upside, analysts clearly believe Opko Health is more favorable than Astrazeneca PLC.
Astrazeneca PLC pays an annual dividend of $1.37 per share and has a dividend yield of 4.2%. Opko Health does not pay a dividend. Astrazeneca PLC pays out 44.9% of its earnings in the form of a dividend.
Earnings and Valuation
This table compares Opko Health and Astrazeneca PLC’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Opko Health||$1.18 billion||2.83||-$17.02 million||($0.17)||-35.12|
|Astrazeneca PLC||$21.74 billion||3.79||$5.91 billion||$3.05||10.67|
Astrazeneca PLC has higher revenue and earnings than Opko Health. Opko Health is trading at a lower price-to-earnings ratio than Astrazeneca PLC, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Opko Health has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Astrazeneca PLC has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
Institutional and Insider Ownership
22.5% of Opko Health shares are owned by institutional investors. Comparatively, 14.2% of Astrazeneca PLC shares are owned by institutional investors. 40.2% of Opko Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Opko Health and Astrazeneca PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Astrazeneca PLC beats Opko Health on 9 of the 15 factors compared between the two stocks.
About Opko Health
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with our FREE daily email newsletter.